239 words / 1 min read

FEEDBACK REQUESTED: CPSM has launched a public consultation on moving non-exempted codeine products to the Manitoba Prescribing Practices Program (M3P) and is requesting feedback from physicians, stakeholders, and the general public.

• This proposal would include Tylenol #2 and Tylenol #3.

THE BIG PICTURE: Codeine contributes to more overdose deaths than any other opioid in Manitoba. The majority of these deaths are accidental and involve a combination of codeine and other sedating medications. In Manitoba, the prescribing of codeine remains more prevalent than any other opioid. 

• View the data on prescribing and codeine use in Manitoba

PROPOSED CHANGE: The working group recommended that all non-exempted codeine-containing products be included under the Manitoba Prescribing Practices Program (M3P) drug list. This change requires approval from both the College of Pharmacists of Manitoba Council (CPhM) and CPSM. CPhM Council approved the addition in September of 2024. This CPSM public consultation is intended to collect feedback regarding adding non-exempted codeine products to the M3P drug list.

• Click here to see a list of all codeine-containing products that are exempted, non-exempted and already on the M3P drug list.

DEADLINE: Review the consultation materials including proposed changes, data, background information, and rationale. Feedback is due by February 18, 2025.

When sharing your views with CPSM, please copy us at practiceadvice@​doctorsmanitoba.​ca. Alternatively, you can share your views with Doctors Manitoba in confidence, and we will integrate them with other feedback into our response to CPSM.